CSBio CSBio

X
[{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Zelluna Immunotherapy"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Targovax"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.

            Lead Product(s): Apricoxib,Stimulon

            Therapeutic Area: Oncology Product Name: TG01

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Agenus

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.

            Lead Product(s): TCR based Natural Killer cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Lion TCR

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY